Intestinal ultrasound is an accurate, noninvasive tool in the detection of postoperative Crohn’s disease recurrence, according to research presented at the Crohn’s and Colitis Congress.

A device used in South Jersey is being called a real game-changer for millions of people with inflammatory bowel disease. This is for people who suffer from things like Crohn's disease and colitis. It ...

Findings on intestinal ultrasound (IUS) are useful for predicting remission in recent-onset Crohn’s disease (CD), a prospective, population-based cohort of newly diagnosed patients in Denmark ...

Intestinal ultrasound is an accurate, noninvasive tool in the detection of postoperative Crohn’s disease recurrence, according to research presented at the Crohn’s and Colitis Congress. &ldquo ...

Characterizing intestinal strictures of Crohn’s disease in vivo by endoscopic photoacoustic imaging. Biomedical Optics Express , 2019; 10 (5): 2542 DOI: 10.1364/BOE.10.002542 Cite This Page : ...

Dhiya was diagnosed with Crohn’s disease at age 10 and had a long journey to find the right treatment, including medical imaging and hospitalization. Recently she tried out intestinal ultrasound, a ...

Diagnosis of Crohn's disease (CD) is often challenging and requires the utmost precision and perseverance in defining location, extent, severity and type of disease (inflammatory vs stricturing ...

Hou: For our last discussion, we'll be going over the abstract, "Early intestinal ultrasound remission is associated with endoscopic healing after one year of infliximab therapy in Crohn's disease ...

IBD, which comprises Crohn’s disease and ulcerative colitis, affects 1.3% of the U.S. population and accounts for 3 million new diagnoses every year. It is an autoimmune disease and can be treated ...

While features of Crohn's disease have been reported to differ in adult-onset versus pediatric-onset patients, with the latter at higher risk of complications, one study found that the cumulative ...

In the highly competitive market for inflammatory diseases such as Crohn's, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as developing new ones.